Tango Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

TNGX$24.30+6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Collaboration revenue	$—	$3,181	$—	$8,573
Operating expenses:
Research and development	37,199	32,807	70,734	69,249
General and administrative	22,586	11,341	37,821	22,821
Total operating expenses	59,785	44,148	108,555	92,070
Loss from operations	(59,785)	(40,967)	(108,555)	(83,497)
Other income:
Interest income	3,723	1,239	5,900	2,853
Other income, net	722	910	1,801	1,984
Total other income, net	4,445	2,149	7,701	4,837
Loss before income taxes	(55,340)	(38,818)	(100,854)	(78,660)
Provision for income taxes	(1)	(35)	(2)	(69)
Net loss	$(55,341)	$(38,853)	$(100,856)	$(78,729)
Net loss per common share – basic and diluted	$(0.37)	$(0.35)	$(0.68)	$(0.71)
Weighted average number of common shares outstanding – basic and diluted	149,875,939	110,540,836	148,660,404	110,494,397
Net loss	$(55,341)	$(38,853)	$(100,856)	$(78,729)
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities	(518)	(100)	(857)	(242)
Comprehensive loss	$(55,859)	$(38,953)	$(101,713)	$(78,971)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.